dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Jimenez-Fonseca, Paula |
dc.contributor.author | Martinez-Torron, Alba |
dc.contributor.author | Alsina Maqueda, Maria |
dc.contributor.author | Custodio, Ana |
dc.contributor.author | Serra, Olbia |
dc.contributor.author | Carmona-Bayonas, Alberto |
dc.date.accessioned | 2022-02-22T11:44:39Z |
dc.date.available | 2022-02-22T11:44:39Z |
dc.date.issued | 2021-01 |
dc.identifier.citation | Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, et al. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Ther Adv Med Oncol. 2021 Jan;13:1–13. |
dc.identifier.issn | 1569-8041 |
dc.identifier.uri | https://hdl.handle.net/11351/7066 |
dc.description | Quimioteràpia; Càncer gàstric; Trastuzumab |
dc.description.sponsorship | The authors received no financial support for the research, authorship, and/or publication of this article. |
dc.language.iso | eng |
dc.publisher | SAGE Publications |
dc.relation.ispartofseries | Therapeutic Advances in Medical Oncology;13 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Esòfag - Càncer - Tractament |
dc.subject | Estómac - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Esophageal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /therapeutic use |
dc.title | External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1177/17588359211019672 |
dc.subject.decs | neoplasias del esófago |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1177/17588359211019672 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Jimenez-Fonseca P] Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain. [Carmona-Bayonas A] Medical Oncology Department, Hospital Universitario Morales Meseguer, 30007 Murcia, Spain. [Martinez-Torron A] Pharmacy Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Alsina M] Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Custodio A] Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain. [Serra O] Medical Oncology Department, Catalan Institute of Oncology, L’Hospitalet, Spain |
dc.identifier.pmid | 34211587 |
dc.identifier.wos | 000688566300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |